Evaluating early inflammatory polyarthritis for better treatment outcomes
Early Prediction of Patient-related and Radiological Outcomes in Patients With Recent-onset Inflammatory Polyarthritis (EPA) Using Established and Novel Independent Predictors
This study is trying to find out if certain blood markers can help doctors identify early on which patients with inflammatory polyarthritis, especially rheumatoid arthritis, might need stronger treatment to avoid severe disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Université de Sherbrooke Academic / other |
| Locations | 1 site (Sherbrooke, Quebec) |
| Trial ID | NCT00512239 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prognostic markers in patients with early inflammatory polyarthritis, particularly focusing on rheumatoid arthritis. It seeks to identify which patients are likely to experience persistent and severe disease based on the presence of specific autoantibodies, such as anti-Sa and anti-CCP antibodies. By evaluating these markers over a period of 60 months, the study intends to improve treatment strategies by determining who should receive aggressive therapy early in their disease course. The study is conducted at the Centre hospitalier universitaire de Sherbrooke in Quebec, Canada.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with early rheumatoid arthritis or early inflammatory arthritis.
Not a fit: Patients with infectious arthritis or microcrystalline arthritis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more targeted and effective treatment strategies for patients with early inflammatory arthritis, potentially reducing long-term disability.
How similar studies have performed: Other studies have shown promise in using biomarkers for risk stratification in rheumatoid arthritis, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Early Rheumatoid arthritis * Early Inflammatory Arthritis Exclusion Criteria: * Refusal or inability to consent * Infectious arthritis * Microcrystalline arthritis
Where this trial is running
Sherbrooke, Quebec
- Centre hospitalier universitaire de Sherbrooke — Sherbrooke, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Gilles Boire, MD, MSc — Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Study coordinator: Gilles Boire, MD, MSc
- Email: Gilles.Boire@USherbrooke.ca
- Phone: (819) 564-5261
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.